Q2 EPS Estimate for Larimar Therapeutics Reduced by Analyst

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Equities research analysts at Wedbush decreased their Q2 2025 EPS estimates for shares of Larimar Therapeutics in a research note issued on Wednesday, April 30th. Wedbush analyst L. Chico now forecasts that the company will post earnings per share of ($0.47) for the quarter, down from their prior forecast of ($0.41). The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.40) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($1.12) EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.04).

A number of other brokerages have also weighed in on LRMR. Robert W. Baird reduced their price target on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating for the company in a research note on Tuesday, March 25th. HC Wainwright lifted their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday, March 25th. Truist Financial initiated coverage on Larimar Therapeutics in a report on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and set a $26.00 target price on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Finally, Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a research report on Tuesday, March 25th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $19.63.

Larimar Therapeutics Stock Up 3.8 %

LRMR stock opened at $2.97 on Monday. The company has a 50-day simple moving average of $2.36 and a 200 day simple moving average of $4.20. The company has a market capitalization of $190.16 million, a P/E ratio of -2.58 and a beta of 0.91. Larimar Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $11.20.

Hedge Funds Weigh In On Larimar Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fi3 FINANCIAL ADVISORS LLC lifted its holdings in shares of Larimar Therapeutics by 16.7% in the fourth quarter. Fi3 FINANCIAL ADVISORS LLC now owns 23,798 shares of the company's stock valued at $92,000 after purchasing an additional 3,411 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Larimar Therapeutics by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company's stock valued at $143,000 after acquiring an additional 3,425 shares in the last quarter. Envestnet Asset Management Inc. increased its holdings in shares of Larimar Therapeutics by 12.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 35,525 shares of the company's stock valued at $137,000 after purchasing an additional 3,877 shares during the period. Bank of America Corp DE lifted its position in shares of Larimar Therapeutics by 8.1% in the fourth quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock worth $206,000 after purchasing an additional 3,980 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Larimar Therapeutics by 35.1% during the fourth quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock worth $75,000 after purchasing an additional 5,042 shares during the period. Institutional investors and hedge funds own 91.92% of the company's stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.